Research programme: CXCR3 antagonists - BioXell/Zambon

Drug Profile

Research programme: CXCR3 antagonists - BioXell/Zambon

Latest Information Update: 09 Dec 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioXell SpA; Zambon Group SpA
  • Class Small molecules
  • Mechanism of Action CXCR3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 28 Feb 2005 Discontinued - Preclinical for Inflammation in Italy (PO)
  • 18 Feb 2004 Preclinical trials in Inflammation in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top